Elevating Proficiency of Evolving Treatment Options for Advanced Hodgkin Lymphoma

i3 Health has provided an educational activity that has alleviated clinician's knowledge gaps pertaining to the evolving landscape of advanced classical Hodgkin lymphoma (HL). Hodgkin lymphoma is a malignancy involving the lymph nodes and lymphatic system. The American Cancer Society estimated in 2022 that there would be 8,540 new cases of HL in the United States, with 920 resulting in death. In contrast with other cancers whose risk increases with age, the risk for HL increases in patients betw...

Continue reading

Improving Outcomes in Hodgkin Lymphoma With Louis Diehl, MD

Oncology Data Advisor™ · Improving Outcomes in Hodgkin Lymphoma Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed each year in the United States (Siegel et al, 2021). While the advent of novel therapies is leading to significantly improved outcomes, HL treatment continues to be associated with an increased risk for secondary cancers and cardiovascular disease (NCCN, 2021; Kreissl et al, 2020). In order to mi...

Continue reading

i3 Health and Oncology Data Advisor Announce ODACon 2022, a Rare Hematologic Malignancies Symposium

ROCHELLE PARK, NJ—January 12, 2022 – i3 Health and Oncology Data Advisor have announced that ODACon, a Rare Hematologic Malignancies Symposium, will be held on January 29, 2022. This 1-day virtual conference features 5 exclusive sessions on emerging data in hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), myelodysplastic syndromes (MDS), and Waldenstrom macroglobulinemia (WM), all presented by expert faculty. Attendees can...

Continue reading

Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma With Kami Maddocks, MD, and Kelly Brassil, PhD, RN, FAAN

Hodgkin lymphoma is a rare malignancy involving the lymph nodes and lymphatic system, with 8,830 new cases diagnosed and accounting for 960 deaths each year in the United States (Siegel et al, 2021). In contrast with other cancers whose risk increases with age, the risk for HL increases in patients between 15 and 30 years of age, decreases during middle age, and is followed by another peak in adults older than 55 (NCCN, 2020). There are 2 main types of HL: classical HL, which accounts for 95% of...

Continue reading

Pembrolizumab Approved for Classical Hodgkin Lymphoma

PembrolizumabThe FDA has now expanded the approved indications for pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme) to include both adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy. The approval was based on efficacy data from the open-label phase 3 KEYNOTE-204 trial (NCT02684292), for which 304 adult patients with cHL previously treated with at least one multiagen...

Continue reading

Modern Radiation Therapy Doses for Early-Stage Hodgkin Lymphoma: Chelsea Pinnix, MD, PhD

While radiation therapy is an effective treatment for patients with early-stage favorable Hodgkin lymphoma, it also poses a risk of long-term toxicity to the surrounding organs and tissue. In a study recently published in JAMA Network Open, a team of researchers led by first author Chelsea Pinnix, MD, PhD, of MD Anderson Cancer Center, found that combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and contemporary radiation therapy (RT) demonstrated effic...

Continue reading

Modern Radiation Plus Chemo Effective and Safe for Early-Stage Hodgkin Lymphoma

According to the results of a new study, combined modality therapy consisting of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) followed by contemporary radiation therapy (RT) was effective and safe in patients with early-stage favorable Hodgkin lymphoma, with low radiation doses delivered to at-risk organs. "While maximal efficacy is demonstrated with combined modality therapy, RT is often omitted in fear of late adverse effects," write the investigators, led by first author Chelsea C. Pi...

Continue reading

Treatment Challenges and Advances in Hodgkin Lymphoma: Craig Moskowitz, MD, and Kami Maddocks, MD

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital at The Ohio State University, share their perspectives on the management of relapsed/refractory classical Hodgkin lymphoma (HL) and the advances brought to the treatment of this disease by dev...

Continue reading

Childhood Hodgkin Lymphoma Increases Long-Term Cancer Risk

Unfortunately, cancer survivors have to be mindful that their cancer has a possibility of returning. Childhood survivors of Hodgkin lymphoma are no exception; they have an increased risk of developing subsequent malignant neoplasms (SMNs). In order to better understand this risk, researchers from the University of Alabama at Birmingham revisited a study that had enrolled 1,136 patients diagnosed with Hodgkin lymphoma prior to age 17 between 1955 and 1986, following them for a median of 26.6 year...

Continue reading

Nivolumab for Untreated Advanced Classic Hodgkin Lymphoma

Nivolumab (Opdivo®, Bristol-Myers Squibb), an anti–programmed cell death protein 1 (anti–PD-1) monoclonal antibody, has been previously approved by the FDA for the treatment of refractory classic Hodgkin lymphoma (cHL). Now, in the CheckMate 205 phase 2 clinical trial, nivolumab shows promise in newly diagnosed advanced-stage cHL. In addition to refractory cHL, nivolumab is approved for the treatment of advanced lung cancer, melanoma, advanced kidney cancer, head and neck squamous cell cancer, a...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.